VACCINEX, INC.
VCNX · OTCMCIK 1205922fmd_15D606Q230HFAA7XMTAFA89RYGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2024, 32 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Cost of revenue | – | 0 | 1 | 0 | 0 | – | – | – | – |
| Gross profit | – | (0) | (0) | 0 | 1 | – | – | – | – |
| Research and development | – | 17 | 22 | 26 | 22 | 17 | 14 | 17 | 13 |
| Operating income | – | (21) | (27) | (32) | (28) | (22) | (20) | (23) | (19) |
| Interest expense | – | 1 | 0 | – | 0 | 1 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | (0) | 0 | 0 | (0) | 0 | 0 | 1 | 0 |
| Income before taxes | – | (19) | (30) | (32) | (29) | (22) | (20) | (20) | (19) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (19) | (30) | (32) | (29) | (22) | (20) | (20) | (19) |
| Net income | – | (19) | (30) | (32) | (29) | (22) | (20) | (20) | (19) |